NMRA Q4 2021 Earnings — Neumora Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

NMRANeumora Therapeutics, Inc. Common Stock

$586M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$27M

Net Income

-$27M

EPS (Diluted)

$-0.18

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$429M

Total Liabilities

$755M

Stockholders' Equity

-$325M

Cash & Equivalents

$409M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$27M	-$20M	-35.9%
Net Income	-$27M	-$20M	-34.9%